Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis

Current Medical Research and Opinion

Volumn 24, Issue 6, 2008, Pages 1691-1702

  Desrosiers, Martin ^a,f   Ferguson, Berrylin ^b   Klossek, Jean Michel ^c   Drugeon, Henri ^d   Mösges, Ralph ^e  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c University of Poitiers   (France)

^d CHU de Nantes   (France)

^e UNIVERSITY OF COLOGNE   (Germany)

^f MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

lactam resistance; Antibacterial agents; Haemophilus influenzae; Ketolides; Sinusitis; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; TELITHROMYCIN;

ABDOMINAL PAIN; ACUTE SINUSITIS; ADULT; BACTERIAL INFECTION; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN ALLERGY; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; VAGINA MYCOSIS; VERTIGO; VISUAL ACUITY;

ACUTE DISEASE; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAM RESISTANCE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; KETOLIDES; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES; SINUSITIS; STREPTOCOCCUS PNEUMONIAE;

EID: 46449108782     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802133914     Document Type: Conference Paper

References (48)

1. Gwaltney JM. Acute community-acquired sinusitis. Clin Infect Dis 1996;23:1209-25
2. Desrosiers M, Klossek JM, Benninger M. Management of acute bacterial rhinosinusitis: current issues and future perspectives. Int J Clin Pract 2006;60:190-200
3. Leggett JE. Acute sinusitis. When - and when not - to prescribe antibiotics. Postgrad Med J 2004;115:13-19
4. Winstead W. Rhinosinusitis. Prim Care 2003;30:137-54
5. Klossek JM, Federspil P. Update on treatment guidelines for acute bacterial sinusitis. Int J Clin Pract 2005;59:230-8
6. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130(1 Suppl):1-45, Erratum in: Otolaryngol Head Neck Surg 2004;130:794-6
7. Low DE, Desrosiers M, McSherry J, et al. A practical guide for the diagnosis and treatment of acute sinusitis. CMAJ 1997;156(Suppl 6):S1-14
8. Rosenfeld RM, Andes D, Bhattacharyya N, et al. Clinical practice guideline: adult sinusitis. Otolaryngol Head Neck Surg 2007;137(3 Suppl):S1-31
9. Riffer E, Spiller J, Palmer R, et al. Once daily clarithromycin extended-release vs twice-daily amoxicillin/clavulanate in patients with acute bacterial sinusitis: a randomized, investigator-blinded study. Curr Med Res Opin 2005;21:61-70
10. Siegert R, Gehanno P, Nikolaidis P, et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000;94:337-44
11. Henry DC, Sydnor A, Settipane GA, et al. Comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of acute bacterial sinusitis. Clin Ther 1999;21:1158-70
12. Lasko B, Lau CY, Saint-Pierre C, et al. Efficacy and safety of oral levofloxacin compared with clarithromycin in the treatment of acute sinusitis in adults: a multicentre, double-blind, randomized trial. J Int Med Res 1998;26:281-91
13. Clifford K, Huck W, Shan M, et al. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Ann Otol Rhinol Laryngol 1999;108:360-7
14. Adelglass J, deAbate CA, McElvaine P, et al. Comparison of the effectiveness of levofloxacin and amoxicillin-clavulanate for the treatment of acute sinusitis in adults. Otolaryngol Head Neck Surg 1999;120:320-7
15. Stefansson P, Jacovides A, Jablonicky P, et al. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998;36:173-8
16. Camacho AE, Cobo R, Otte J, et al. Clinical comparison of cefuroxime axetil and amoxicillin/clavulanate in the treatment of patients with acute bacterial maxillary sinusitis. Am J Med 1992;93:271-6
17. Dubois J, Saint-Pierre C, Tremblay C. Efficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J 1993;72:804-10
18. Haye R, Lingaas E, Hoivik HO, Odegard T. Azithromycin versus placebo in acute infectious rhinitis with clinical symptoms but without radiological signs of maxillary sinusitis. Eur J Clin Microbiol Infect Dis 1998;17:309-12
19. Karma P, Pukander J, Penttilä M, et al. The comparative efficacy and safety of clarithromycin and amoxycillin in the treatment of outpatients with acute maxillary sinusitis. J Antimicrob Chemother 1991;27(Suppl A):83-90
20. Lindbaek M, Hjortdahl P, Johnsen UL. Randomised, double blind, placebo controlled trial of penicillin V and amoxycillin in treatment of acute sinus infections in adults. BMJ 1996;313:325-9
21. Matthews BL, Kohut RI, Edelstein DR, et al. Evaluation of Cefixime in the treatment of bacterial maxillary sinusitis. South Med J 1993;86:329-33
22. von Sydow C, Savolainen S, Soderqvist A. Treatment of acute maxillary sinusitis - comparing Cefpodoxime proxetil with amoxicillin. Scand J Infect Dis 1995;27:229-34
23. Hoban DJ, Zhanel GG. Clinical implications of macrolide resistance in community-acquired respiratory tract infections. Expert Rev Anti Infect Ther 2006;4:973-80
24. Doern GV. Optimizing the management of community-acquired respiratory tract infections in the age of antimicrobial resistance. Expert Rev Anti Infect Ther 2006;4:821-35
25. Johnson DM, Stilwell MG, Fritsche TR, Jones RN. Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006;56:69-74
26. Felmingham D, White AR, Jacobs MR, et al. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 2005;56(Suppl 2):ii3-21
27. Jenkins SG, Farrell DJ, Patel M, Lavin BS. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000-2003: PROTEKT US years 1-3. J Infect 2005;51:355-63
28. Poole MD. Acute bacterial rhinosinusitis: clinical impact of resistance and susceptibility. Am J Med 2004;117(Suppl 3A):29-38S
29. White AR, Kaye C, Poupard J, et al. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004;53(Suppl 1):i3-20
30. Poole MD, Portugal LG. Treatment of rhinosinusitis in the outpatient setting. Am J Med 2005;118(Suppl 7A):45-50S
31. Pichichero ME. Short courses of antibiotic in acute otitis media and sinusitis infections. J Int Med Res 2000;28(Suppl 1):25-36A
32. Kasbekar N, Acharya PS. Telithromycin: the first ketolide for the treatment of respiratory infections. Am J Health Syst Pharm 2005;62:905-16
33. Buchanan P, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. Am J Rhinol 2003;17:369-77
34. Ferguson BJ, Guzzetta RV, Spector SL, Hadley JA. Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;131:207-14
35. Luterman M, Tellier G, Lasko B, Leroy B. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. Ear Nose Throat J 2003;82:576-90
36. Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002;48:100-8
37. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006;118(Suppl 5):S17-61
38. US FDA. Guidance for industry. Sinusitis: designing clinical development programs of nonantimicrobial drugs for treatment. 2006 http://www.fda.gov/cder/ guidance/7316dft.pdf (accessed 1 February 2008)
39. International Conference on Harmonisation (ICH). Harmonised Tripartite Guideline. Guideline for good clinical practice E6(R1), 10 June 1996. http://www.ich.org/LOB/media/MEDIA482.pdf (accessed 31 January 2008)
40. Taylor DC, Norman GR, Torrance G, et al. Validation of 5-item instrument for assessing symptom severity in patients with acute bacterial sinusitis. Value Health 2004;7:766
41. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston: New England Medical Center, The Health Institute, 1993
42. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Component Summary Measures: A User's Manual. Boston: New England Medical Center, The Health Institute, 1994
43. US FDA. Telithromycin (marketed as Ketek) Information. Updated February 12, 2007. http://www.fda.gov/CDER/Drug/infopage/telithromycin/default.htm (accessed 31 January 2008)
44. Muller-Serieys C, Andrews J, Vacheron F, Cantalloube C. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004;53:149-57
45. Farrell DJ, Felmingham D. Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003. Antimicrob Agents Chemother 2004;48:1882-4
46. Parnham MJ. Immunomodulatory effects of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis 2005;18:125-31
47. Araujo FG, Slifer TL, Remington JS. Inhibition of secretion of interleukin-1α and tumor necrosis factor alpha by the ketolide antibiotic telithromycin. Antimicrob Agents Chemother 2002;46:3327-30
48. Nicolau DP, Tessier PR, Rubinstein I, Nightingale CH. In vivo immunomodulatory profile of telithromycin in a murine pneumococcal infection model. Pharmazie 2006;61:343-7